359 related articles for article (PubMed ID: 28589238)
21. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
Jiang ZD; DuPont HL; La Rocco M; Garey KW
J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
[TBL] [Abstract][Full Text] [Related]
23. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
26. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
27. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
28. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
29. Summaries for patients. Can antibiotics improve the symptoms of the irritable bowel syndrome?
Ann Intern Med; 2006 Oct; 145(8):I24. PubMed ID: 17043334
[No Abstract] [Full Text] [Related]
30. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Rezaie A; Heimanson Z; McCallum R; Pimentel M
Am J Gastroenterol; 2019 Dec; 114(12):1886-1893. PubMed ID: 31688023
[TBL] [Abstract][Full Text] [Related]
31. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
Garey KW; Ghantoji SS; Shah DN; Habib M; Arora V; Jiang ZD; DuPont HL
J Antimicrob Chemother; 2011 Dec; 66(12):2850-5. PubMed ID: 21948965
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.
Menees SB; Maneerattannaporn M; Kim HM; Chey WD
Am J Gastroenterol; 2012 Jan; 107(1):28-35; quiz 36. PubMed ID: 22045120
[TBL] [Abstract][Full Text] [Related]
35. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
Collins BS; Lin HC
J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
[TBL] [Abstract][Full Text] [Related]
36. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
37. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Ann Intern Med; 2005 May; 142(10):805-12. PubMed ID: 15897530
[TBL] [Abstract][Full Text] [Related]
39. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.
Gawronska A; Banasiuk M; Lachowicz D; Pituch H; Albrecht P; Banaszkiewicz A
Inflamm Bowel Dis; 2017 Dec; 23(12):2209-2214. PubMed ID: 29084080
[TBL] [Abstract][Full Text] [Related]
40. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
